PHO: Photocure Partner Asieris Announces Completion of Patient Enrollment in Cevira Phase III Clinical Trial
2022-08-09 09:38:13
On August 9, 2022, Asieris Pharmaceuticals, a global biopharmaceutical company
specializing in the discovery and development of innovative drugs for the
treatment of genitourinary tumors and other major diseases, announced that the
multinational Phase III Clinical Trial of APL-1702 (Cevira[®]), a novel non
-surgical treatment of cervical high-grade squamous intraepithelial lesions
(HSIL), has successfully enrolled 402 patients in the study two months ahead of
schedule. Additionally, Photocure received a $1 million milestone payment from
Asieris related to the ongoing clinical development of Cevira.
APRICITY is a multicenter, prospective, double-blind, randomized controlled
Phase III study further evaluating the efficacy and safety of the integrated
drug-and light-delivery device Cevira[®] in the treatment of HSIL. The clinical
trial was approved by the National Medical Products Administration (NMPA) in
July 2020 and was conducted simultaneously at 65 sites in 8 countries including
China, Germany, Hungary and the Netherlands. The first patient was dosed in
November 2020.
Cervical cancer is the fourth most common cancer in women worldwide[1]. In 2020,
604,000 new cases and 342,000 deaths worldwide were attributed to cervical
cancer.[1,2 ]Current treatments of HSIL of the cervix are based on invasive
surgical interventions, compromising cervical competence and functionality.
Currently, no non-surgical approach is available for the treatment of
precancerous cervical lesions.
Read Asieris' full press release here: https://asieris.com/asieris-multinational
-phase-iii-clinical-trial-for-the-non-surgical-treatment-of-hsil-has-completed
-enrollment/
1. Cervical cancer. Available from: https://www.who.int/health-topics/cervical
-cancer
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021